Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Classical Hodgkin Lymphoma: early-phase trial registry
4 of 9 indexed Classical Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Classical Hodgkin Lymphoma: 9 US clinical trials tracked, 4 recruiting.
Classical Hodgkin Lymphoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Tessa Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition classical-hodgkin-lymphoma
OPEN 4 | RECR 44% | LATE 0 | EARLY 9 | RANK #1916 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Classical Hodgkin Lymphoma lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Classical Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Classical Hodgkin Lymphoma is recruiting below its size-band peers.
4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Classical Hodgkin Lymphoma trials is spread across many organizations.
Tessa Therapeutics accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Classical Hodgkin Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 18 among the 9 trials that report a genuine target (sentinel values excluded). 7 of those (77.8%) plan for fewer than 100 participants.
-
Classical Hodgkin Lymphoma research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme
NCT02332668
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
NCT05362773
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
University of Virginia
NCT05404945
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Baylor College of Medicine
NCT04288726
Itacitinib + Everolimus in Hodgkin Lymphoma
University of Pennsylvania
NCT03697408
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
NCT02940301
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
Tessa Therapeutics
NCT05352828
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
NCT03236935
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
NCT06870487
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Classical Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Classical Hodgkin Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Classical Hodgkin Lymphoma page
9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Classical Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Tessa Therapeutics sponsors the most Classical Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See Tessa Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Classical Hodgkin Lymphoma condition card totals 9 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.